# Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II

> **NCT07134712** · PHASE2 · NOT_YET_RECRUITING · sponsor: **HONYA Medical Co Ltd** · enrollment: 102 (estimated)

## Conditions studied

- Acute Myocardial Infarction (AMI)

## Interventions

- **BIOLOGICAL:** Cord Blood Nucleated cells

## Key facts

- **NCT ID:** NCT07134712
- **Lead sponsor:** HONYA Medical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07134712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07134712, "Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07134712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*